AbbVie (ABBV)

This top-shelf exchange-traded fund (ETF) checks all the right boxes for income- and value-seeking investors.

Investors would need to have over $330,000 invested in this Vanguard dividend ETF.

AbbVie's third-quarter earnings were disappointing, but the company raised its full-year guidance and increased the dividend.

The stocks listed here were all up more than 19% in 2022, while the S&P 500 crashed.

As of December 18, 2025, the financial landscape is undergoing a significant transformation, forcing retirees to reconsider their high-octane growth strategies in favor of more stable, income-generating assets. Following a year dominated by artificial intelligence speculation and aggressive tech rallies, a mid-December rotation has seen investors pulling capital away from

Can one ETF deliver decades of dividend income? This unique high-quality yield generator deserves a spot on your watchlist.

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

These habitual market beaters can pull it off again.

They could grow into their valuation over the next few years.

See what solid dividends do for a portfolio after just five years.

Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that most have already exploited their existing market opportunities and must invest heavily to expand further, a risky proposition.

The drugmaker has plenty to offer investors.

Guardian Wealth Management raised its stake in LKQ stock to nearly $4.9 Million during the third quarter of 2025.

Guardian Wealth bought over 133,000 shares of Viper Energy during the third quarter of 2025.

New York, NY – December 9, 2025 – The S&P 500 Healthcare sector found itself in a precarious position today, emerging as the biggest underperformer among its peers. While the broader S&P 500 index largely treaded water, the healthcare segment registered a notable decline of 0.5%, extending a three-day

Blockbuster drugs are a major driver of the growth of healthcare stocks.

Great dividends are only part of the attraction with these stocks.

This drugmaker has a strong portfolio of best-selling drugs and a growing pipeline.

Don't bet against it.

These ETFs can provide me with lots of passive income.

New York, NY – December 3, 2025 – In a significant move reverberating through the biotechnology sector, investment banking giant Morgan Stanley has downgraded Regeneron Pharmaceuticals (NASDAQ: REGN) from "Overweight" to "Equal-Weight." The firm maintained its price target of $767.00, signaling that, in their view, the stock is now fairly valued

These healthcare leaders can make you money while you sleep.

These stocks have been raising their dividend payments annually for well over a decade, and they pay more than twice the S&P 500 average.

From high-yield pharma plays to growth-oriented compounders, these eight stocks offer something for every dividend investor.